Intravenous Iron Replacement Therapy Improves Cardiovascular Outcomes in Hemodialysis Patients.
Anaemia
cardiovascular disease
echocardiography
haemodialysis
iron
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
27
02
2021
revised:
12
03
2021
accepted:
23
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
More than half of deaths among hemodialysis patients are due to cardiovascular disease. This study examined whether intravenous administration of ferric carboxymaltose (FCM) has an impact on cardiovascular events in iron-deficient hemodialysis patients. We performed a retrospective study concerning patients undergoing hemodialysis in our center from September 2016 to December 2019. We identified those who began FCM therapy (FCM group) during this period and those who did not (control group). We analyzed clinical, echocardiographic and laboratory parameters at the beginning (t0) and after one year (t1), to detect differences between the two groups. We identified 53 patients for the FCM group and 19 for the control group. Median follow-up was 1 year±3 months for both groups. In the FCM group, we observed a reduction in the doses of erythropoiesis-stimulating agents (ESA) (p<0.001) and a significative difference in cardiovascular events (p<0.01), but no differences in echocardiographic parameters. Patients who received FCM reached satisfactory values of transferrin saturation and ferritin, presented fewer coronary artery events and cardiovascular events, and could reduce doses of ESA.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
More than half of deaths among hemodialysis patients are due to cardiovascular disease. This study examined whether intravenous administration of ferric carboxymaltose (FCM) has an impact on cardiovascular events in iron-deficient hemodialysis patients.
PATIENTS AND METHODS
METHODS
We performed a retrospective study concerning patients undergoing hemodialysis in our center from September 2016 to December 2019. We identified those who began FCM therapy (FCM group) during this period and those who did not (control group). We analyzed clinical, echocardiographic and laboratory parameters at the beginning (t0) and after one year (t1), to detect differences between the two groups.
RESULTS
RESULTS
We identified 53 patients for the FCM group and 19 for the control group. Median follow-up was 1 year±3 months for both groups. In the FCM group, we observed a reduction in the doses of erythropoiesis-stimulating agents (ESA) (p<0.001) and a significative difference in cardiovascular events (p<0.01), but no differences in echocardiographic parameters.
CONCLUSION
CONCLUSIONS
Patients who received FCM reached satisfactory values of transferrin saturation and ferritin, presented fewer coronary artery events and cardiovascular events, and could reduce doses of ESA.
Identifiants
pubmed: 33910844
pii: 35/3/1617
doi: 10.21873/invivo.12419
pmc: PMC8193293
doi:
Substances chimiques
Hematinics
0
Iron
E1UOL152H7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1617-1624Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Eur Heart J. 2015 Mar 14;36(11):657-68
pubmed: 25176939
Nephron Clin Pract. 2009;113(1):c38-45
pubmed: 19590234
Am J Kidney Dis. 2006 Jan;47(1):24-36
pubmed: 16377382
Nephrol Dial Transplant. 2007 Mar;22(3):794-800
pubmed: 17210593
Semin Dial. 2018 May;31(3):258-267
pubmed: 29624739
Am J Kidney Dis. 2006 May;47(5 Suppl 3):S16-85
pubmed: 16678661
Clin Kidney J. 2016 Oct;9(5):729-34
pubmed: 27679720
Int J Artif Organs. 2011 Jun;34(6):481-8
pubmed: 21725929
Blood Purif. 2011;31(1-3):113-20
pubmed: 21228578
Nephrol Dial Transplant. 2006 Jan;21(1):120-4
pubmed: 16144853
Am J Kidney Dis. 2009 May;53(5):823-34
pubmed: 19339087
Am J Kidney Dis. 2016 Apr;67(4):548-58
pubmed: 26763385
Nephrol Dial Transplant. 2018 Apr 1;33(4):690-699
pubmed: 29036505
J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):802-815
pubmed: 30178922
Haematologica. 2014 Nov;99(11):1671-6
pubmed: 25420283
ESC Heart Fail. 2018 Oct;5(5):800-808
pubmed: 30015405
BMC Nephrol. 2019 Jan 7;20(1):5
pubmed: 30616548
Am J Kidney Dis. 2012 Jan;59(1):108-16
pubmed: 21890255
N Engl J Med. 2019 Jan 31;380(5):447-458
pubmed: 30365356
Nephron Clin Pract. 2014;128(3-4):323-32
pubmed: 25503585
Semin Nephrol. 2006 Jul;26(4):261-8
pubmed: 16949463
N Engl J Med. 2009 Dec 17;361(25):2436-48
pubmed: 19920054
J Am Coll Cardiol. 2011 Sep 13;58(12):1241-51
pubmed: 21903058
Nephrol Dial Transplant. 2005 Aug;20(8):1686-92
pubmed: 15840664
Eur J Heart Fail. 2017 Apr;19(4):522-530
pubmed: 27647766
Eur J Heart Fail. 2015 Mar;17(3):329-39
pubmed: 25683972
Nat Rev Cardiol. 2011 May 31;8(9):485-93
pubmed: 21629210
Clin Nephrol. 1978 May;9(5):205-9
pubmed: 657597
Am J Nephrol. 2018;47(2):72-83
pubmed: 29439253
J Am Coll Cardiol. 1997 Feb;29(2):448-54
pubmed: 9015003
Eur J Heart Fail. 2013 Oct;15(10):1164-72
pubmed: 23703106
Nephrol News Issues. 2006 Aug;20(9):38-9
pubmed: 16916060
Am J Kidney Dis. 1996 Jul;28(1):53-61
pubmed: 8712222
J Card Fail. 2011 Nov;17(11):899-906
pubmed: 22041326
Am J Kidney Dis. 2002 Nov;40(5):1005-12
pubmed: 12407646
Heart Fail Clin. 2010 Jul;6(3):295-304
pubmed: 20630404
Circulation. 2018 Jul 3;138(1):80-98
pubmed: 29967232
Int J Cardiol. 2014 Jun 15;174(2):268-75
pubmed: 24768464
Eur J Heart Fail. 2018 May;20(5):910-919
pubmed: 29484788
Am J Kidney Dis. 2009 May;53(5):815-22
pubmed: 19324483